FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1995452486> ?p ?o ?g. }

• W1995452486 abstract "<h3>Background</h3> The development of immuno-oncologic agents poses unique challenges, namely that both efficacy and safety profiles differ from previously characterized cytotoxic and pathway-specific agents. In addition, exponential distribution is usually assumed in study designs with time-to-event endpoints such as overall survival or progression-free survival. This assumption might lead to wrong estimates of study duration and statistical power if the phenomena of long term survival and delayed clinical effects are present. The aim here was to evaluate the magnitude of the impact caused by the violation of this assumption, and to describe new ways of analyzing efficacy and safety of immuno-oncologic agents. <h3>Methods</h3> Monte Carlo simulation was implemented to explore the impact of long term survivors and delayed treatment effect on study power and trial duration. Scenarios with various combinations of long term and delayed treatment effects were considered. Study power and duration were evaluated based on 10000 randomly generated trial data sets. The utility of group sequential study designs was discussed. A new set of immune-related response criteria (irRC) was considered for efficacy analysis. Two new methods for identifying adverse events, termed immune-related adverse events (irAE) and immune-mediated adverse reactions (imAR) were described. The key features of the safety profiles derived using these two methods were similar. Both methods were aimed at identifying inflammatory adverse events caused by immunotherapies. <h3>Results</h3> The presence of long term survivors usually lengthened the study duration. Depending on the treatment effect post survival curve separation, delayed clinical effect in general led to a loss of power. The irRC offered a new way of identifying clinical responses. Both safety analyses demonstrated higher sensitivity of identifying adverse events of immune system origin. <h3>Conclusion</h3> This simulation study showed the importance of accounting for the delayed treatment effect and long term survivors when these phenomena were expected. Interim analyses for the purpose of stopping the study for either positive or futile outcome should be implemented with caution in immuno-oncology trials. The new efficacy analysis offered a potential new way of assessing signs of activity in immunotherapies. While the irAE method facilitated prompt and effective management of adverse events, the imAR method captured truly immune-related events." @default.
• W1995452486 created "2016-06-24" @default.
• W1995452486 creator A5033937088 @default.
• W1995452486 date "2013-10-21" @default.
• W1995452486 modified "2023-10-13" @default.
• W1995452486 title "Statistical issues and challenges in immuno-oncology" @default.
• W1995452486 cites W1828940258 @default.
• W1995452486 cites W1908752382 @default.
• W1995452486 cites W1912223290 @default.
• W1995452486 cites W1969094789 @default.
• W1995452486 cites W1984130041 @default.
• W1995452486 cites W2019607817 @default.
• W1995452486 cites W2031330193 @default.
• W1995452486 cites W2059707463 @default.
• W1995452486 cites W2061893665 @default.
• W1995452486 cites W2068834940 @default.
• W1995452486 cites W2089401318 @default.
• W1995452486 cites W2095826876 @default.
• W1995452486 cites W2097995306 @default.
• W1995452486 cites W2100158834 @default.
• W1995452486 cites W2103075930 @default.
• W1995452486 cites W2103220202 @default.
• W1995452486 cites W2119198740 @default.
• W1995452486 cites W2123363005 @default.
• W1995452486 cites W2127151679 @default.
• W1995452486 cites W2129449089 @default.
• W1995452486 cites W2129623370 @default.
• W1995452486 cites W2136746908 @default.
• W1995452486 cites W2139248078 @default.
• W1995452486 cites W2149752186 @default.
• W1995452486 cites W2163983995 @default.
• W1995452486 cites W2164130643 @default.
• W1995452486 cites W2164918836 @default.
• W1995452486 cites W2166379450 @default.
• W1995452486 cites W2166768348 @default.
• W1995452486 cites W2999126745 @default.
• W1995452486 cites W4242589154 @default.
• W1995452486 cites W4301655662 @default.
• W1995452486 doi "https://doi.org/10.1186/2051-1426-1-18" @default.
• W1995452486 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4019889" @default.
• W1995452486 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24829754" @default.
• W1995452486 hasPublicationYear "2013" @default.
• W1995452486 type Work @default.
• W1995452486 sameAs 1995452486 @default.
• W1995452486 citedByCount "130" @default.
• W1995452486 countsByYear W19954524862014 @default.
• W1995452486 countsByYear W19954524862015 @default.
• W1995452486 countsByYear W19954524862016 @default.
• W1995452486 countsByYear W19954524862017 @default.
• W1995452486 countsByYear W19954524862018 @default.
• W1995452486 countsByYear W19954524862019 @default.
• W1995452486 countsByYear W19954524862020 @default.
• W1995452486 countsByYear W19954524862021 @default.
• W1995452486 countsByYear W19954524862022 @default.
• W1995452486 countsByYear W19954524862023 @default.
• W1995452486 crossrefType "journal-article" @default.
• W1995452486 hasAuthorship W1995452486A5033937088 @default.
• W1995452486 hasBestOaLocation W19954524861 @default.
• W1995452486 hasConcept C10515644 @default.
• W1995452486 hasConcept C112758219 @default.
• W1995452486 hasConcept C124952713 @default.
• W1995452486 hasConcept C126322002 @default.
• W1995452486 hasConcept C142362112 @default.
• W1995452486 hasConcept C143998085 @default.
• W1995452486 hasConcept C177264268 @default.
• W1995452486 hasConcept C197934379 @default.
• W1995452486 hasConcept C199360897 @default.
• W1995452486 hasConcept C41008148 @default.
• W1995452486 hasConcept C535046627 @default.
• W1995452486 hasConcept C71924100 @default.
• W1995452486 hasConceptScore W1995452486C10515644 @default.
• W1995452486 hasConceptScore W1995452486C112758219 @default.
• W1995452486 hasConceptScore W1995452486C124952713 @default.
• W1995452486 hasConceptScore W1995452486C126322002 @default.
• W1995452486 hasConceptScore W1995452486C142362112 @default.
• W1995452486 hasConceptScore W1995452486C143998085 @default.
• W1995452486 hasConceptScore W1995452486C177264268 @default.
• W1995452486 hasConceptScore W1995452486C197934379 @default.
• W1995452486 hasConceptScore W1995452486C199360897 @default.
• W1995452486 hasConceptScore W1995452486C41008148 @default.
• W1995452486 hasConceptScore W1995452486C535046627 @default.
• W1995452486 hasConceptScore W1995452486C71924100 @default.
• W1995452486 hasIssue "1" @default.
• W1995452486 hasLocation W19954524861 @default.
• W1995452486 hasLocation W19954524862 @default.
• W1995452486 hasLocation W19954524863 @default.
• W1995452486 hasLocation W19954524864 @default.
• W1995452486 hasLocation W19954524865 @default.
• W1995452486 hasOpenAccess W1995452486 @default.
• W1995452486 hasPrimaryLocation W19954524861 @default.
• W1995452486 hasRelatedWork W117204087 @default.
• W1995452486 hasRelatedWork W1607015646 @default.
• W1995452486 hasRelatedWork W2064879719 @default.
• W1995452486 hasRelatedWork W2085830368 @default.
• W1995452486 hasRelatedWork W2091213729 @default.
• W1995452486 hasRelatedWork W2139557367 @default.
• W1995452486 hasRelatedWork W2389807988 @default.
• W1995452486 hasRelatedWork W2896776551 @default.
• W1995452486 hasRelatedWork W3146899016 @default.
• W1995452486 hasRelatedWork W4385315152 @default.

• next